Advertisement

Psychological Effects of Cholinomimetic Agents

  • D. S. Janowsky
  • J. M. Davis

Abstract

Janowsky, Davis and colleagues began in 1972 to explore the possibility that the affective disorders, mania and depression, might be due to a complex balance, or inter-action, between adrenergic and cholinergic factors (Janowsky et al., 1972a). Proposed most simply, mania was hypothesized to be a syndrome due to relatively diminished central acetylcholine (ACh) activity, compared to normal or increased noradrenergic and/or dopaminergic activity; and depression was proposed to be the converse (Janowsky et al., 1972b).

Keywords

Affective Disorder Manic Symptom Dopaminergic Activity Cholinergic Activity Antimanic Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Beigel, A., and Murphy, D.L., 1971, Assessing clinical characteristics of the manic state, Am. J. Psychiatry 128: 688.PubMedGoogle Scholar
  2. Bowers, M.B., Goodman, E., and Sim, V.M., 1964, Some behavioral changes in man following anticholinesterase administration, J. Nerv. Merit. Dis. 138: 383.CrossRefGoogle Scholar
  3. Brown, H., 1971, Some anticholinergic-like behavioral effects of trans (-) - Δ8-tetrahydro-cannabinol, Psychopharmacologia 21: 294.PubMedCrossRefGoogle Scholar
  4. Carroll, B.J., Frazer, A., Schless, A., and Mendels, A., 1973, Cholinergic reversal of manic symptoms, Lancet 7: 427.CrossRefGoogle Scholar
  5. Casey, D.E., and Denney, D., 1977, Pharmacological characterization of tardive dyskinesia, Psychopharmacology 54: 1.PubMedCrossRefGoogle Scholar
  6. Cutler, R.P., and Kurland, H.D., 1961, Clinical quantification of depressive reactions, Arch. Gen. Psychiatry 5: 88.Google Scholar
  7. Davis, J.M., 1970, Theories of the biological etiology of affective disorders, Int. Rev. Neurobiol. 72: 145.CrossRefGoogle Scholar
  8. Davis, J.M., Janowsky, D.S., Tamminga, C., and Smith, R.C., 1976, Cholinergic Mechanisms and Psychopharmacology (D.J. Jenden, ed.), Plenum Publishing Corporation, New York.Google Scholar
  9. Davis, K.L., Hollister, L.E., Overall, J., Johnson, A., and Train, K., 1976, Physostigmine: effects on cognition and affect in normal subjects, Psychopharmacology 51: 23.PubMedCrossRefGoogle Scholar
  10. Davis, K.L., Hollister, L.E., Goodwin, F.K., and Gordon, E.K., 1977, Neurotransmitter metabolites in the cerebrospinal fluid ofman following physostigmine, Life Sci. 21: 933.PubMedCrossRefGoogle Scholar
  11. Davis, K.L., Berger, P.A., Hollister, L.E., and Defraites, E., 1978, Physostigmine in mania, Arch. Gen. Psychiatry 35(1)J: 119.Google Scholar
  12. El-Yousef, M.K., Janowsky, D.S., Davis, J.M., and Rosenblatt, J.R., 1973, Induction of severe depression by physostigmine in marijuana intoxicated individuals, Br. J. Addict. 68: 321.CrossRefGoogle Scholar
  13. Fibiger, J.D., Lynch, G.S., and Cooper, H.P., 1971, A biphasic action of central cholinergic stimulation on behavioral arousal in the rat, Psychopharmacologia 20: 366.PubMedCrossRefGoogle Scholar
  14. Gershon, S., and Shaw, F.H., 1961, Psychiatric sequelae of chronic exposure to organo-phosphorous insecticides, Lancet I: 1371.CrossRefGoogle Scholar
  15. Goodman, L.S., and Gilman, A., (eds.), 1970, “The Pharmacological Basis of Therapeutics, 4th Ed.,” Collier-MacMillan, Toronto, Canada.Google Scholar
  16. Gorny, D., Billewicz-Stankiewicz, J., Zajqczkowska, M., and Kutarski, A., 1976, Effect of noradrenaline on the content, synthesis and catabolism of acetylcholine in the brain, Acta Physiol. Pol 27: 55.PubMedGoogle Scholar
  17. Janowsky, D.S., El-Yousef, M.K., Davis, J.M., Sekerke, H.J., and Hubbard, B.J., 1972a, Cholinergic antagonism of manic symptoms, Lancet 7: 1236.CrossRefGoogle Scholar
  18. Janowsky, D.S., El-Yousef, M.K., Davis, J.M., and Sekerke, H.J., 1972b, A cholinergicadrenergic hypothesis of mania and depression, Lancet II: 632.CrossRefGoogle Scholar
  19. Janowsky, D.S., El-Yousef, M.K., Davis, J.M., Sekerke, H.J., 1972c, Cholinergic antagonism of methylphenidate-induced stereotyped behavior, Psychopharmacologia 27: 295.CrossRefGoogle Scholar
  20. Janowsky, D.S., El-Yousef, M.K., Davis, J.M., and Sekerke, H.J., 1973a, Parasympathetic suppression of manic symptoms by physostigmine, Arch. Gen. Psychiatry 28: 542.PubMedGoogle Scholar
  21. Janowsky, D.S., Davis, J.M., El-Yousef, M.K., and Sekerke, H.J., 1973b, Acetylcholine and depression, Psychosom. Med. 35 (5): 56S.Google Scholar
  22. Janowsky, D.S., El-Yousef, M.K., and Sekerke, H.J., 1973c, Antagonistic effects of physostigmine and methylphenidate in man, Am. J. Psychiatry 130: 1310.Google Scholar
  23. Mandell, A.J., and Knapp, S., 1971, The effects of chronic administration of some cholinergic and adrenergic drugs on the activity of choline acetyltransferase in the optic lobe of the chick brain, Neuropharmacology 10: 513.PubMedCrossRefGoogle Scholar
  24. Meduna, L.J., and Abood, L.G., 1959, Studies of a new drug (DITRAN) in depressive states, J. Neuropsychiatry 1: 20.Google Scholar
  25. Modestin, J.J., Hunger, R.B., and Schwartz, R.B., 1973a, Uber die depressogene Wirkung von Physostigmin, Arch. Psychiatr. Nervenkr. 218: 61.CrossRefGoogle Scholar
  26. Modestin, J.J., Schwartz, R.B., and Hunger, J., 1973b, Zur frage der beeinflussung schizo-phrener Symptome physostigmin, Pharmakopsychiatrie 9: 300.CrossRefGoogle Scholar
  27. Rosenblatt, J.E., Janowsky, D.S., Davis, J.M., and El-Yousef, M.K., 1972, The augmentation of physostigmine toxicity in the rat by Δ9-tetrahydrocannabinol, Res. Commun. Chem. Pathol. Pharmacol. 3(3): 419.Google Scholar
  28. Rowntree, D.W., Neven, S., and Wilson, A., 1950, The effects of diisopropylfluorophos- phonate in schizophrenic and manic depressive psychosis, J. Neurol. Neurosurg. Psychiatry 13: 41.CrossRefGoogle Scholar
  29. Safer, D.J., and Allen, R.P., 1971, The central effects of scopolamine in man, Biol. Psychiatry 3: 341.Google Scholar
  30. Schildkraut, J.J., 1965, The catecholamine hypothesis of affective disorders: a review of supporting evidence, Am. J. Psychiatry 122: 509.PubMedGoogle Scholar
  31. Shopsin, B., Janowsky, D.S., Davis, J.M., and Gershon, S., 1975, Rebound phenomena in manic patients following physostigmine, Neuropsychobiology 7: 180.CrossRefGoogle Scholar
  32. Snyder, S.H., and Yamamura, H.I., 1977, Antidepressants and the muscarinic acetylcholine receptor, Arch. Gen. Psychiatry 34: 236.PubMedGoogle Scholar
  33. Stadler, H., Lloyd, K.G., Gadea-Cira, M., and Bartholini, G., 1973, Enhanced striatal acetylcholine release by chlorpromazine and its reversal by apomorphine, Brain Res. 55: 416.CrossRefGoogle Scholar
  34. Sulser, F., Bickel, M.H., and Brodie, B.B., 1964, The action of desmethylimipramine in counteracting sedation and cholinergic effects of reserpine-like drugs, J. Pharmacol. Exp. Ther. 144: 321.Google Scholar
  35. Tamminga, C., Smith, R.C., Chang, S., Haraszti, J.S., and Davis, J.M., 1976, Depression associated with oral choline, Lancet II: 905.Google Scholar
  36. Trabucchi, M., Cheney, D.L., Racagni, G., and Costa, E., 1975, In vivo inhibition of striatal acetylcholine turnover by L-DOPA, apomorphine and (+) -amphetamine, Brain Res. 85: 130.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1979

Authors and Affiliations

  • D. S. Janowsky
    • 1
  • J. M. Davis
    • 1
  1. 1.Department of PsychiatryUniversity of California at San Diego, School of MedicineLa JollaUSA

Personalised recommendations